Xenetic Biosciences Announces Departure of Two Board Members
| XBIO Stock | USD 2.91 0.10 3.32% |
About 62% of Xenetic Biosciences' investor base is looking to short. The analysis of overall sentiment of trading Xenetic Biosciences stock suggests that many investors are alarmed at this time. Xenetic Biosciences' investing sentiment overview a quick insight into current market opportunities from investing in Xenetic Biosciences. Many technical investors use Xenetic Biosciences stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
On October 29, 2024, Xenetic Biosciences, Inc. reported in a Form 8-K filing to the Securities and Exchange Commission that James E. Callaway and Adam Logal, members of the companys board of directors, have chosen not to stand for re-election at the upcoming 2024 Annual Meeting of Stockholders. The decision made by Dr. Callaway
Read at thelincolnianonline.com
 |
Xenetic Biosciences Fundamental Analysis
We analyze Xenetic Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xenetic Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xenetic Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Xenetic Biosciences is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Xenetic Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Xenetic Biosciences stock to make a market-neutral strategy. Peer analysis of Xenetic Biosciences could also be used in its relative valuation, which is a method of valuing Xenetic Biosciences by comparing valuation metrics with similar companies.
Peers
Xenetic Biosciences Related Equities
| TNXP | Tonix Pharmaceuticals | 21.21 | ||||
| GOVX | GeoVax Labs | 4.08 | ||||
| ENVB | Enveric Biosciences | 3.17 | ||||
| REVB | Revelation Biosciences | 2.95 | ||||
| IMMX | Immix Biopharma | 2.43 | ||||
| ZVSA | ZyVersa Therapeutics | 1.96 | ||||
| NBY | NovaBay Pharmaceuticals | 1.72 | ||||
| SONN | Sonnet Biotherapeutics | 1.55 | ||||
| PALI | Palisade Bio | 1.47 | ||||
| PHIO | Phio Pharmaceuticals | 0.54 | ||||
| VRAX | Virax Biolabs | 0.93 | ||||
| ATNF | 180 Life | 2.54 | ||||
| ZURA | Zura Bio | 2.70 | ||||
| DRUG | Bright Minds | 3.06 | ||||
| RNAZ | Transcode Therapeutics | 17.89 |
Check out Xenetic Biosciences Hype Analysis, Xenetic Biosciences Correlation and Xenetic Biosciences Performance. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.